Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 5
2021 11
2022 7
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.
Muzurović EM, Volčanšek Š, Tomšić KZ, Janež A, Mikhailidis DP, Rizzo M, Mantzoros CS. Muzurović EM, et al. J Cardiovasc Pharmacol Ther. 2022 Jan-Dec;27:10742484221146371. doi: 10.1177/10742484221146371. J Cardiovasc Pharmacol Ther. 2022. PMID: 36546652 Free article. Review.
Thyroid Status and Vascular Risk: An Update.
Muzurović E, Borozan S, Vujošević S, Gurnell M. Muzurović E, et al. Curr Vasc Pharmacol. 2022;20(6):460-462. doi: 10.2174/1570161120666221004144414. Curr Vasc Pharmacol. 2022. PMID: 36200192 No abstract available.
Non-alcoholic Fatty Liver Disease in Children.
Muzurović E, Polyzos SA, Mikhailidis DP, Borozan S, Novosel D, Cmiljanić O, Kadić N, Mantzoros CS. Muzurović E, et al. Curr Vasc Pharmacol. 2023;21(1):4-25. doi: 10.2174/1570161121666221118155136. Curr Vasc Pharmacol. 2023. PMID: 36411561 Review.
29 results